Статьи из журналов

Background Main body Conclusion

Metastatic castration-resistant prostate cancer (mCRPC) remains a therapeutic challenge, particularly in patients with suboptimal response to 177Lu PSMA-617. Terbium-161 (Tb-161), with its emission of β-particles and high-LET Auger/conversion electrons, offers potential advantages in targeting micro

To identify predictive biomarkers of early progression in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy (RLT). This retrospective single-center study included all consecutive mCRPC patients who initiated [¹⁷⁷Lu]Lu-PSMA-617

The androgen axis is an important growth driver in prostate cancer, with androgen blockade a cornerstone treatment for metastatic prostate cancer. Prostate-specific membrane antigen (PSMA) radioligand therapy is also playing an increasingly important role in the treatment of metastatic castration-re

Background Results Conclusions

Theranostics, integrating diagnostic imaging with targeted radionuclide therapy, has become central to nuclear medicine, but its global research landscape and collaboration patterns remain incompletely mapped. To characterize publication dynamics, cooperative networks, and emerging topics in theran

Purpose: Targeted radionuclide therapy with 177Lu-PSMA-617 prolongs radiographical progression-free survival in prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC), yet 13% of patients develop symptomatic skeletal events. The authors hypothesize

Background Results Conclusion

Background Methods Results Conclusion

The purpose of this investigation was to formulate and evaluate a chemically optimized [225Ac]Ac-labeled radioimmunoconjugate targeting the insulin-like growth factor-2 receptor (IGF2R) for targeted alpha therapy of osteosarcoma, a disease with unchanging survival rates for over 40 years. The anti-I

PSMA-targeted radioligand therapy is a promising approach for the treatment of advanced prostate cancer; however, the clinical efficacy of [177Lu]Lu-PSMA-617 (Pluvicto®) is limited by the relatively low cytotoxic potency of the β-emitting radionuclide 177Lu (t1/2: 6.65 d). This has driven high inter